GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocata Therapeutics Inc (NAS:OCAT) » Definitions » Days Inventory

Ocata Therapeutics (Ocata Therapeutics) Days Inventory : 0.00 (As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is Ocata Therapeutics Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Ocata Therapeutics's Average Total Inventories for the three months ended in Sep. 2015 was $0.00 Mil. Ocata Therapeutics's Cost of Goods Sold for the three months ended in Sep. 2015 was $0.02 Mil. Hence, Ocata Therapeutics's Days Inventory for the three months ended in Sep. 2015 was 0.00.

The historical rank and industry rank for Ocata Therapeutics's Days Inventory or its related term are showing as below:

OCAT's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 192.335
* Ranked among companies with meaningful Days Inventory only.

Ocata Therapeutics's Days Inventory stayed the same from Sep. 2014 (0.00) to Sep. 2015 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ocata Therapeutics's Inventory-to-Revenue for the three months ended in Sep. 2015 was 0.00.


Ocata Therapeutics Days Inventory Historical Data

The historical data trend for Ocata Therapeutics's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocata Therapeutics Days Inventory Chart

Ocata Therapeutics Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Days Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ocata Therapeutics Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Days Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ocata Therapeutics's Days Inventory

For the Biotechnology subindustry, Ocata Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocata Therapeutics's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocata Therapeutics's Days Inventory distribution charts can be found below:

* The bar in red indicates where Ocata Therapeutics's Days Inventory falls into.



Ocata Therapeutics Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Ocata Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2014 is calculated as

Days Inventory (A: Dec. 2014 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2013 ) + Total Inventories (A: Dec. 2014 )) / count ) / Cost of Goods Sold (A: Dec. 2014 )*Days in Period
=( (0 + 0) / 1 ) / 0.063*365
=0 / 0.063*365
=0.00

Ocata Therapeutics's Days Inventory for the quarter that ended in Sep. 2015 is calculated as:

Days Inventory (Q: Sep. 2015 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Jun. 2015 ) + Total Inventories (Q: Sep. 2015 )) / count ) / Cost of Goods Sold (Q: Sep. 2015 )*Days in Period
=( (0 + 0) / 1 ) / 0.015*365 / 4
=0 / 0.015*365 / 4
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocata Therapeutics  (NAS:OCAT) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Ocata Therapeutics's Inventory Turnover for the three months ended in Sep. 2015 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Ocata Therapeutics's Inventory to Revenue for the three months ended in Sep. 2015 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


Ocata Therapeutics Days Inventory Related Terms

Thank you for viewing the detailed overview of Ocata Therapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocata Therapeutics (Ocata Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Ocata Therapeutics Inc was incorporated in Nevada under the name Two Moon Kachinas Corp. on May 18, 2000. The Company is a biotechnology company, engaged in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. It is actively conducting clinical trials for treating dry age-related macular degeneration and Stargardt's macular degeneration, in addition to several clinical and preclinical programs for other ocular therapies. It also has a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. Its intellectual property portfolio includes pluripotent human embryonic stem cell, or hESC; induced pluripotent stem cell, or iPSC, platforms; and other cell therapy research programs. It has developed a human photoreceptor progenitor cell. In the U.S., one of the Company's ongoing clinical trials is a Phase 1/2 study for treating dry AMD patients by injection of RPE cells made in culture from an hESC line. It is also conducting Phase 1/2 studies in both the U.S. and the U.K. for the treatment of SMD patients using the RPE cell injections. The Company is conducting three trials in cooperation with retinal surgeons at the top eye hospitals in the U.S. and the U.K. including: Jules Stein Eye Institute (UCLA), Wills Eye Institute, Bascom Palmer Eye Institute (University of Miami) and Massachusetts Eye and Ear Infirmary. As of March 27, 2014, the Company had 46 issued patents and 178 pending patent applications filed, a substantial portion of which pertain to its active product development programs. The Company competes with Pfizer, Regenerative Patch Technologies and the Riken Center for Developmental Biology (Japan), among others. The Company's research and development activities are subject to regulation for safety and efficacy by numerous governmental authorities in the United States and other countries.
Executives
Brian Levy director
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Edward H Myles officer: COO & CFO C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Paul K Wotton director, officer: President and CEO C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Jooste H Le Roux officer: SVP of Bus Development & CCO C/O NABI BIOPHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Gregory D Perry director C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Michael D West director AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501
Pedro Huertas officer: Chief Development Officer 950 WINTER STREET, NORTH, WALTHAM MA 02451
Alan G Walton director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 385 E. COLORADO BLVD., SUITE 299, PASADENA CA 91101
Robert Peabody director, officer: VP - Grant Administration ONE INNOVATION DRIVE, WORCHESTER MA 01605

Ocata Therapeutics (Ocata Therapeutics) Headlines

No Headlines